CJC-1295 (No DAC) & Ipamorelin Blend:
The Maxoratide CJC-1295 (No DAC) / Ipamorelin Blend is a refined combination of two well-studied growth hormone secretagogues. This dual-peptide formulation is designed to harness the complementary mechanisms of a Growth Hormone-Releasing Hormone (GHRH) analogue and a Growth Hormone Secretagogue (GHS), making it a valuable tool for research focused on endogenous hormone signaling pathways.
Mechanism of Action: Dual-Pathway Stimulation
In laboratory research settings, this blend is investigated for its ability to enhance the amplitude and natural pulsatility of growth hormone (GH) release through two distinct mechanisms:
- CJC-1295 (No DAC): Acts as a GHRH analogue that binds to GHRH receptors in the anterior pituitary, stimulating the synthesis and release of growth hormone. The “No DAC” variant is characterized by a shorter half-life, allowing it to better replicate natural physiological GH pulse dynamics.
- Ipamorelin: Functions as a selective ghrelin receptor agonist, supporting GH release by reducing somatostatin activity and promoting the secretion of stored growth hormone from the pituitary gland.
Key Research Focus Areas
- Hypertrophic Signaling: Studied for its influence on IGF-1 expression and its downstream effects on cellular repair, muscle protein synthesis, and bone remodeling.
- Metabolic Function: Investigated for potential effects on basal metabolic rate, lipid oxidation, and nitrogen balance in experimental models.
- Receptor Selectivity: Ipamorelin is noted for its high receptor specificity, with research suggesting minimal impact on prolactin, cortisol, or ACTH levels, making it valuable for clean endocrine signaling
